Company intelligence / Profile preview
Exeltis
Madrid, Spainexeltis.com ↗
- Ownership
- Private
- Employees
- ~4000
- Development stage
- Other
01
Overview
Exeltis has successfully commercialized several women’s health products globally. Its estrogen-free contraceptive Slynd underwent extensive clinical trials involving approximately 3,000 women across phases I–III before approval. The company also markets a range of prenatal vitamins and treatments for vaginal infections.
- Therapeutic areas
- Women's HealthNeurologyInfectious Diseases
- Modalities
- Small molecules (e.g., oral contraceptives like drospirenone)Nutritional supplements (e.g., prenatal vitamins)Medical devices
- Industry
- Biotech
02
Drug pipeline
11 assets10 more assets in the full pipeline.
Beyond the preview
Go deeper on Exeltis.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Exeltis.